Skip to main content
ACRS logo

ACRS · Aclaris Therapeutics, Inc. · Executive Compensation

Track ACRS — free
$3.48 -0.02 (-0.57%) Q1 2024 earnings call transcript
Market Cap
$555.14M
Shares
158.61M
Volume · Nov 19 1.89M Avg daily vol (3M) 3.05M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Neal Walker $3,375,591
Kevin Balthaser $1,490,790
James Loerop $1,447,106
Fiscal 2024
Executive Total
Neal Walker $1,445,135
Kevin Balthaser $1,102,163
Fiscal 2023
Executive Total
Douglas Manion $7,157,681
Gail Cawkwell $2,403,312
Kevin Balthaser $2,344,432
James Loerop $2,332,912
Joseph Monahan $2,255,344
Fiscal 2022
Executive Total
Gail Cawkwell $3,299,008
Douglas Manion $3,202,198
Joseph Monahan $2,822,982
Fiscal 2021
Executive Total
Neal Walker $6,854,936
Joseph Monahan $5,327,305
Kamil Ali-Jackson $4,687,106
Frank Ruffo $3,262,768
David Gordon $2,921,109
Fiscal 2020
Executive Total
Neal Walker $1,610,678
Frank Ruffo $811,609
Kamil Ali-Jackson $767,574
David Gordon $760,225
Fiscal 2019
Executive Total
Neal Walker $3,149,533
David Gordon $1,372,176
Frank Ruffo $1,162,390

Executive changes

Person Change Filed
William Humphries Appointed 2025-06-05
Andrew Schiff, M.D. Appointed 2025-06-05
Neal Walker Appointed 2025-06-05
Steven Knapp Appointed 2024-11-18
Hugh Davis Appointed 2024-11-18
Hugh Davis Appointed 2024-11-18
Hugh Davis Appointed 2024-11-18
Andrew Powell
“Mr. Powell’s resignation from the Board was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2024-03-19
Gail Cawkwell, M.D., PhD. Terminated 2024-02-05
Neal Walker Appointed 2024-01-19
Douglas Manion
“Dr. Manion's resignation from the Board was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
Resigned 2024-01-19
Douglas Manion
“Dr. Manion's resignation from the Board was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
Resigned 2024-01-19
Kevin Balthaser Appointed 2023-01-06
Douglas Manion Appointed 2023-01-06
Kevin Balthaser Appointed 2022-11-22
Douglas Manion Appointed 2022-11-22
Douglas Manion Appointed 2022-11-22
Frank Ruffo
“Mr. Ruffo’s retirement was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Retired 2022-11-22
Neal Walker Appointed 2022-11-22
Neal Walker
“Dr. Walker’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2022-11-22
Douglas Manion Appointed 2022-08-01
Kamil Ali-Jackson Retired 2021-11-02

Leadership

Key facts CIK 1557746 CUSIP 00461U105 13F (30d) 182 filings 159 filers Visit website Investor relations